Premium Nahrungsergänzungsmittel | artgerecht

Rivaroxaban – Uses, Dosage and Side Effects

Rivaroxaban is a prescription anticoagulant medication belonging to the class of direct oral anticoagulants. It is used to prevent and treat blood clots such as deep vein thrombosis and pulmonary embolism.

Regular tips about health Regular tips about health

Things worth knowing about "Rivaroxaban"

Rivaroxaban is a prescription anticoagulant medication belonging to the class of direct oral anticoagulants. It is used to prevent and treat blood clots such as deep vein thrombosis and pulmonary embolism.

What is Rivaroxaban?

Rivaroxaban is a direct oral anticoagulant (DOAC) and belongs to the drug class of Factor Xa inhibitors. It is marketed under the brand name Xarelto and is one of the most widely prescribed blood-thinning medications worldwide. Unlike older anticoagulants such as warfarin, rivaroxaban does not require routine blood monitoring (INR testing), making it more convenient for patients.

Indications

Rivaroxaban is approved for several medical indications:

Prevention of deep vein thrombosis (DVT) following major orthopedic surgery (e.g., hip or knee replacement)
Treatment and secondary prevention of DVT and pulmonary embolism (PE)
Stroke prevention in patients with non-valvular atrial fibrillation
Prevention of heart attack and stroke in patients with coronary artery disease or peripheral artery disease (combined with aspirin)

Mechanism of Action

Rivaroxaban selectively and reversibly inhibits coagulation Factor Xa, which plays a central role in the blood clotting cascade. By blocking Factor Xa, the formation of thrombin (Factor IIa) is reduced, which in turn prevents the conversion of fibrinogen to fibrin and the formation of blood clots (thrombi). Rivaroxaban acts on both free and clot-bound Factor Xa, offering effective anticoagulation.

Dosage

The dosage of rivaroxaban depends on the specific indication:

DVT/PE treatment: 15 mg twice daily for the first 3 weeks, followed by 20 mg once daily (taken with the main meal)
Atrial fibrillation / stroke prevention: 20 mg once daily (with the main meal); 15 mg once daily in patients with moderate renal impairment
DVT prophylaxis after surgery: 10 mg once daily (regardless of meals)
Secondary prevention after acute coronary syndrome (with aspirin): 2.5 mg twice daily

The exact dosage must always be determined by the prescribing physician, especially in patients with impaired kidney or liver function.

Side Effects

Like all anticoagulants, rivaroxaban increases the risk of bleeding. Common and clinically relevant side effects include:

Bleeding events (e.g., nosebleeds, gum bleeding, prolonged bleeding from cuts)
Gastrointestinal bleeding
Anemia due to chronic blood loss
Nausea and gastrointestinal discomfort
Elevated liver enzyme levels (rare)
Serious internal bleeding (rare but potentially life-threatening)

Patients should seek immediate medical attention if they notice signs of serious bleeding, such as blood in urine, black or tarry stools, or sudden severe headache.

Contraindications and Precautions

Rivaroxaban should not be used in patients with:

Active, clinically significant bleeding
Severe liver disease associated with increased bleeding risk
Pregnancy or breastfeeding
Concomitant use of certain medications (e.g., strong CYP3A4 and P-gp inhibitors such as azole antifungals or HIV protease inhibitors)

Special caution is required in patients with impaired renal function, as rivaroxaban is partially excreted by the kidneys.

Important Notes for Patients

Rivaroxaban should be taken regularly and at the same time each day.
The 15 mg and 20 mg doses must be taken with a meal to ensure adequate absorption.
Do not stop taking rivaroxaban without consulting your doctor.
Always inform your doctor or dentist about rivaroxaban use before any surgical or dental procedures.
There is a specific reversal agent available: Andexanet alfa can be used in cases of serious or life-threatening bleeding.

References

European Medicines Agency (EMA): Xarelto (Rivaroxaban) - Summary of Product Characteristics. EMA, 2023.
Camm AJ et al. - 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal, 2021.
Bauersachs R et al. - Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.